

## Publications:

**1.) Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.**

*Markovic S, Paliskyte R, Rottbauer W, Wöhrle J.*  
Cardiovasc Revasc Med. 2012 Nov-Dec;13(6):307-10.

**2.) Standardized radial approach reduces access site complications: a prospective observational registry.**

*Markovic S, Imhof A, Kunze M, Rottbauer W, Wöhrle J.*  
Coron Artery Dis. 2015 Jan;26(1):56-9.

**3.) Zotarolimus compared with everolimus eluting stents-angiographic and clinical results after recanalization of true coronary chronic total occlusions.**

*Markovic S, Lützner M, Rottbauer W, Wöhrle J.*  
Catheter Cardiovasc Interv. 2016 Jul;88(1):18-23.

**4.) Clinical results of single and multiple bioresorbable drug-eluting scaffolds for treatment of de-novo coronary artery disease.**

*Markovic S, Dragomir S, Walcher D, Bernhardt P, Imhof A, Rottbauer W, Wöhrle J.*  
Coron Artery Dis. 2016 Nov;27(7):561-5.

**5.) Percutaneous coronary interventions for ostial lesions.**

*Wöhrle J, Markovic S.*  
Herz. 2016 Nov;41(7):579-584.

**6.) Long-term clinical results of bioresorbable absorb scaffolds using the PSP-technique in patients with and without diabetes.**

*Markovic S, Kugler C, Rottbauer W, Wöhrle J.*  
J Interv Cardiol. 2017 Aug;30(4):325-330.

**7.) Angiographic and clinical outcomes after recanalization of coronary chronic total occlusions with the Orsiro sirolimus-eluting stent compared with the resolute zotarolimus-eluting stent.**

*Markovic S, Lützner M, Dragomir S, Rottbauer W, Wöhrle J.*  
Coron Artery Dis. 2017 Aug;28(5):376-380.

**8.) Comparison of a Point-Of-Care Test for High-Sensitivity C-Reactive Protein with an Established Immuno-Nephelometric Method.**

*Markovic S, Armbruster FP, Dschietzig TB, Koenig W.*  
Clin Lab. 2015;61(10):1585-8.

**9.) Clinical results of the new MitraClip® NT after successful percutaneous edge to edge repair of mitral valve regurgitation**

*Keßler M, Seeger J, Wöhrle J, Rottbauer W, Markovic S.*  
Int J Cardiovasc Res. 2018, Jan; 7(1),

**10.) Predictors of rehospitalization after percutaneous edge-to-edge mitral valve repair by MitraClip implantation**

*Keßler M, Seeger J, Muche R, Wöhrle J, Rottbauer W, Markovic S.*  
Eur J Heart Fail. 2019 Feb;21(2):182-192.

**11.) Intra-aortic balloon counterpulsation pump in heart failure patients during MitraClip implantation – a propensity-score matched analysis.**

*Keßler M, Seeger J, Wöhrle J, Rottbauer W, Markovic S.*

Catheter Cardiovasc Interv. 2018 Dec 1;92(7):1433-1438.

**12.) Atrial Fibrillation Predicts Long-Term Outcome after Transcatheter Edge-to-Edge Mitral Valve Repair by MitraClip Implantation.**

*Keßler M, Pott A, Mammadova E, Seeger J, Wöhrle J, Rottbauer W, Markovic S.*

Biomolecules. 2018 Nov 19;8(4).

**13.) Predictors of left ventricular reverse remodeling after percutaneous therapy for mitral regurgitation with the MitraClip system.**

*Nita N, Scharnbeck D, Schneider L, Seeger, Wöhrle J, Rottbauer W, Keßler M, Markovic S.*

Catheter Cardiovasc Interv. 2020 Feb 27.

**14.) Angiographic Results After Percutaneous Coronary Interventions in Ostial Versus Distal Left Main Lesions.**

*Stephan T, Keßler M, Goldberger N, Rottbauer W, Markovic S.*

Cardiovasc Revasc Med. 2021 Feb;23:22-27.

**15.) Impact of bleeding complications after transcatheter mitral valve repair.**

*Paukovitsch M, Schepperle N, Pott A, Buckert D, Moritz Schneider L, Keßler M, Reichart C, Rottbauer W, Markovic S.*

Int J Cardiol Heart Vasc. 2021 Jan 6;32:100707.

**16.) How to improve navigation during cardioband transcatheter tricuspid annuloplasty.**

*Bertsche D, Keßler M, Buckert D, Schneider LM, Rottbauer W, Rasche V, Markovic S, Vernikouskaya I.*

Eur Heart J Cardiovasc Imaging. 2021 May 10;22(6):611-613. (Geteilte Autorenschaft)

**17.) Impact of Radial Access on Contrast-Induced Acute Kidney Injury in Patients With Coronary Artery Bypass Grafts.**

*Stephan T, Felbel D, Rattka M, Rottbauer W, Markovic S.*

Cardiovasc Revasc Med. 2022 Mar;36:123-131.

**18) Implications of concomitant obstructive or restrictive pulmonary diseases on functional and clinical results after MitraClip.**

*Schneider LM, Nicoleta N, Schepperle N, Paukovitsch M, Haide U, Feuerabendt S, Keßler M, Rottbauer W, Markovic S.*

Catheter Cardiovasc Interv. 2021 Dec 1;98(7): E1000-E1006.

**19.) Prevalence of iatrogenic atrial septal defects (iASD) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) in the long-term follow-up.**

*Paukovitsch M, Schneider LM, Reichart C, Nita N, Rottbauer W, Keßler M, Markovic S.*

Open Heart. 2021 Oct;8(2):e001732.

**20.) Impact of extent of coronary artery disease and percutaneous revascularization assessed by the SYNTAX score on outcomes following transcatheter aortic valve replacement.**

*Stephan T, Thoma E, Rattka M, Felbel D, Buckert D, Rottbauer W, Gonska B, Markovic S.*

BMC Cardiovasc Disord. 2021 Nov 30;21(1):568. (Geteilte Autorenschaft)

**21.) Vascular Access-Site Choice and Outcomes in Patients With Previous Coronary Artery Bypass Surgery Undergoing Coronary Catheterization in a High-Volume Transradial Center.**

Stephan T, Gierl MT, Felbel D, Rattka M, Rottbauer W, Gonska B, **Markovic S**.  
J Invasive Cardiol. 2022 Mar;34(3):E237-E248.

**Publications as Coauthor:**

**30.) Trends in Transcatheter Edge-to-Edge Mitral Valve Repair Over a Decade: Data From the MiTra ULM Registry,**

Nita N, Schneider L, Dahme T, Markovic S, Keßler M, Rottbauer W, Tadic M,  
Front Cardiovasc Med 2022 Mar 8;9:850356

**29.) Epidemiological Trends in Patients Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair over the Last Decade: Functional vs. Structural Mitral Regurgitation.**

Schneider L, Nita N, Dahme T, **Markovic S**, Keßler M, Rottbauer W, Tadic M.  
J Clin Med. 2022 Mar 4;11(5):1422.

**28.) Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2.**

Mangner N, Farah A, Ohlow MA, Möbius-Winkler S, Weilenmann D, Wöhrle J, Linke A, Stachel G, **Markovic S**, Leibundgut G, Rickenbacher P, Cattaneo M, Gilgen N, Kaiser C, Scheller B, Jeger RV; BASKET-SMALL 2 Investigators.  
Circ Cardiovasc Interv. 2022 Feb;15(2):e011325.

**27.) Predicting Phrenic Nerve Palsy in Patients Undergoing Atrial Fibrillation Ablation With the Cryoballoon-Does Sex Matter?**

Pott A, Wirth H, Teumer Y, Weinmann K, Baumhardt M, Schweizer C, **Markovic S**, Buckert D, Bothner C, Rottbauer W, Dahme T.  
Front Cardiovasc Med. 2021 Dec 14;8:746820.

**26.) Non-invasive Imaging in Patients With Chronic Total Occlusions of the Coronary Arteries-What Does the Interventionalist Need for Success?**

Kersten J, Eberhardt N, Prasad V, Keßler M, **Markovic S**, Mörike J, Nita N, Stephan T, Tadic M, Tesfay T, Rottbauer W, Buckert D.  
Front Cardiovasc Med. 2021 Aug 30;8:713625.

**25.) Percutaneous edge-to-edge mitral valve repair for mitral regurgitation improves heart failure symptoms in heart failure with preserved ejection fraction patients.**

Gröger M, Scheffler JK, Schösser F, Schneider LM, Rottbauer W, **Markovic S**, Keßler M.  
ESC Heart Fail. 2021 Dec;8(6):5010-5021. doi: 10.1002/ehf2.13561.

**24.) Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Admitted During COVID-19 Pandemic Lockdown in Germany - Results of a Single Center Prospective Cohort Study.**

Rattka M, Stuhler L, Winsauer C, Dreyhaupt J, Thiessen K, Baumhardt M, **Markovic S**, Rottbauer W, Imhof A. Front Cardiovasc Med. 2021 Apr 20;8:638954

**23.) Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.**

Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Weilenmann D, Wöhrle J, Stachel G, **Markovic S**, Leibundgut G, Rickenbacher P, Osswald S, Cattaneo M, Gilgen N, Kaiser C, Scheller B; BASKET-SMALL 2 Investigators. *Lancet*. 2020 Nov 7;396(10261):1504-1510.

**22.) Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation: A Patient-Level, Multicenter Analysis.**

Jung RG, Simard T, Kovach C, Flint K, Don C, Di Santo P, Adamo M, Branca L, Valentini F, Benito-González T, Fernández-Vázquez F, Estévez-Loureiro R, Berardini A, Conti N, Rapezzi C, Biagini E, Parlow S, Shorr R, Levi A, Manovel A, Cardenal-Piris R, Diaz Fernandez J, Shuvy M, Haberman D, Sala A, Alkhouli MA, Marini C, Bargagna M, Schiavi D, Denti P, **Markovic S**, Buzzatti N, Chan V, Hynes M, Mesana T, Labinaz M, Pappalardo F, Taramasso M, Hibbert B. *JACC Cardiovasc Interv*. 2021 Jan 11;14(1):1-11.

**21.) 31 days of COVID-19-cardiac events during restriction of public life-a comparative study.**

**Rattka M, Baumhardt M, Dreyhaupt J, Rothenbacher D, Thiessen K, Markovic S, Rottbauer W, Imhof A.** *Clin Res Cardiol*. 2020 Dec;109(12):1476-1482.

**20.) A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.**

Dangas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, Möllmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimarães AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schäfer U, Seeger J, Tchétché D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC, Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R, Windecker S; GALILEO Investigators. *N Engl J Med*. 2020 Jan 9;382(2):120-129

**19.) 31 days of COVID-19-cardiac events during restriction of public life-a comparative study.**

**Rattka M, Baumhardt M, Dreyhaupt J, Rothenbacher D, Thiessen K, Markovic S, Rottbauer W, Imhof A.** *Clin Res Cardiol*. 2020 Jun 3:1–7.

**18.) Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique.**

*Reichart C, Wöhrle J, Markovic S, Rottbauer W, Seeger J.* *BMC Cardiovasc Disord*. 2019 Jan 18;19(1):22.

**17.) First experience with the MitraClip XTR device for extensive mitral valve prolapse (Barlow's disease).**

*Weinmann K, Markovic S, Rottbauer W, Keßler M.* *EuroIntervention*. 2018 Dec 20;14(12):e1276-e1277.

**16) Predictors of early scaffold thrombosis: results from the multicenter prospective German-Austrian ABSORB ReglStRy.**

*Wöhrle J, Nef HM, Naber C, Achenbach S, Riemer T, Mehilli J, Münzel T, Schneider S, Markovic S, Seeger J, Rottbauer W, Pfannebecker T, Richardt G, Zahn R, Gori T, Kastner J, Schermund A, Hamm CW; GABI-R Study Group.* *Coron Artery Dis*. 2018 Aug;29(5):389-396.

**15.) Percutaneous mitral valve repair with the MitraClip NT™ system in a patient presenting with prolonged cardiogenic shock.**

*Buckert D, Markovic S, Kunze M, Wöhrle J, Rottbauer W, Walcher D. Clin Case Rep. 2017 Sep 23;5(11):1807-1810.*

**14.) Percutaneous Mitral Valve Repair With the MitraClip in Primary Compared With Secondary Mitral Valve Regurgitation Using the Mitral Valve Academic Research Consortium Criteria.**

*Seeger J, Müller P, Gonska B, Scharnbeck D, Markovic S, Walcher D, Rottbauer W, Wöhrle J. J Invasive Cardiol. 2017 Apr;29(4):145-150.*

**13.) Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison.**

*Kugler C, Markovic S, Rottbauer W, Wöhrle J. Coron Artery Dis. 2017 Mar;28(2):120-125.*

**12.) Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.**

*Rittger H, Wöhrle J, Brachmann J, Hohenforst-Schmidt W, Schlundt C, Lonke S, von Cranach M, Markovic S, Achenbach S, Waliszewski M. Catheter Cardiovasc Interv. 2016 Oct;88(4):529-534.*

**11.) Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial.**

*Wöhrle J, Markovic S, Rottbauer W, Muramatsu T, Kadota K, Vázquez-González N, Odenstedt J, Serra A, Antonucci D, Varenne O, Saito S, Wijns W. EuroIntervention. 2016 Jun 12;12(2):e167-74.*

**10.) Paclitaxel-coated balloon plus bare-metal stent for de-novo coronary artery disease: final 5-year results of a randomized prospective multicenter trial.**

*Seeger J, Markovic S, Birkemeyer R, Rittger H, Jung W, Brachmann J, Rottbauer W, Wöhrle J. Coron Artery Dis. 2016 Mar;27(2):84-8.*

**9.) Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).**

*Rittger H, Waliszewski M, Brachmann J, Hohenforst-Schmidt W, Ohlow M, Brugger A, Thiele H, Birkemeyer R, Kurowski V, Schlundt C, Zimmermann S, Lonke S, von Cranach M, Markovic S, Daniel WG, Achenbach S, Wöhrle J. JACC Cardiovasc Interv. 2015 Nov;8(13):1695-700.*

**8.) Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.**

*Seeger J, Bothner C, Dahme T, Gonska B, Scharnbeck D, Markovic S, Rottbauer W, Wöhrle J. Clin Res Cardiol. 2016 Mar;105(3):225-9.*

**7.) Transfemoral aortic valve implantation with the repositionable Lotus valve compared with the balloon-expandable Edwards Sapien 3 valve.**

*Wöhrle J, Gonska B, Rodewald C, Trepte U, Koch S, Scharnbeck D, Seeger J, Markovic S, Rottbauer W. Int J Cardiol. 2015 Sep 15;195:171-5.*

**6.) Improvement of regional and global left ventricular function in magnetic resonance imaging after recanalization of true coronary chronic total occlusions.**

*Chadid P, Markovic S, Bernhardt P, Hombach V, Rottbauer W, Wöhrle J. Cardiovasc Revasc Med. 2015 Jun;16(4):228-32.*

**5.) Efficacy of different devices for transcatheter closure of patent foramen ovale assessed by serial transoesophageal echocardiography and rates of recurrent cerebrovascular events in a long-term follow-up.**

*Luani B, Markovic S, Krumsdorf U, Rottbauer W, Wöhrle J. EuroIntervention. 2015 May;11(1):85-91.*

**4.) Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds.**

*Wöhrle J, Naber C, Schmitz T, Schwencke C, Frey N, Butter C, Brachmann J, Ingwersen M, Drabik A, Markovic S, Mathey DG. EuroIntervention. 2015 Jun;11(2):149-56.*

**3.) Pulmonary pulse transit time: a novel echocardiographic indicator of hemodynamic and vascular alterations in pulmonary hypertension and pulmonary fibrosis.**

*Wibmer T, Rüdiger S, Scharnbeck D, Radermacher M, Markovic S, Stoiber KM, Rottbauer W, Schumann C. Echocardiography. 2015 Jun;32(6):904-11.*

**2.) Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial.**

*Wöhrle J, von Scheidt F, Schauwecker P, Wiesneth M, Markovic S, Schrezenmeier H, Hombach V, Rottbauer W, Bernhardt P. Clin Res Cardiol. 2013 Oct;102(10):765-70.*

**1.) Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease.**

*Wöhrle J, Birkemeyer R, Markovic S, Nguyen TV, Sinha A, Miljak T, Spiess J, Rottbauer W, Rittger H. Heart. 2011 Aug;97(16):1338-42.*